Vaccines, the process for preparing the same and the applications thereof
Influenza virus vaccine
Serological reagent and preparation thereof
Injectable gamma globulin Patent #: 4165370
ApplicationNo. 06/020786 filed on 03/15/1979
US Classes:530/387.1, Immunoglobulin, antibody, or fragment thereof, other than immunoglobulin antibody, or fragment thereof that is conjugated or absorbed530/361, Separation, purification or synthesis530/389.3, Binds plasma protein, serum protein, or fibrin (e.g., clotting factor, fibrinolytic factor, complement factor, immunoglobulin, apolipoprotein, etc.)530/389.4, Binds virus or component or product thereof (e.g., virus-associated antigen, etc.)530/389.5, Binds bacterium or similar microorganism or component or product thereof (e.g., Pseudomonas, Chlamydia, Clostridium, bacterium-associated antigen, etc.)530/389.6, Binds hematopoietic cell or component or product thereof (e.g., erythrocyte, granulocyte, bone marrow cell, lymphocyte, leukemic cell, hematopoietic cell-surface antigen, hemoglobin, etc.)530/389.7, Binds cancer cell or component or product thereof (e.g., cell-surface antigen, etc.)530/389.8, Binds drug, hapten, hapten-carrier complex, or specifically-identified chemical structure (e.g., theophylline, digoxin, etc.)530/400, Metal containing, e.g., chromoproteins, ferritin, ferredoxins, etc.530/406, Oxygen containing reactant530/421, Polymeric, e.g., polyethylene glycol, etc.530/806, ANTIGENIC PEPTIDES OR PROTEINS530/825, Bacteria530/826, Viruses530/853, Ovary; eggs; embryos530/856, Snakes; venom530/861INVOLVING IGG3, IGG4, IGA, OR IGY
ExaminersPrimary: Fagelson, Anna P.
Attorney, Agent or Firm
International ClassesA23J 1/00 (20060101)
A23J 1/09 (20060101)
C07K 16/02 (20060101)
G01N 33/531 (20060101)
A61K 38/00 (20060101)
Foreign Application Priority Data1978-03-22 ZA
AbstractImmunological preparations are prepared by immunizing hens with an antigen, preferably to a stage of hyperimmunization. The eggs of the immunized hens are collected, the yolk is separated from the eggs, followed by separation of the lipid content of the yolk. The antibodies in the egg yolk are then rendered indispersable with the aid of a water-soluble linear filamentary non-charged polymer precipitant such as PEG and the indispersable antibodies are recovered. This precipitation of antibodies is preferably preceded by a precipitation of caseinaceous proteins at lower polymer concentrations.The immunological preparations are useful for diagnostic purposes and in appropriate cases also for the treatment of pathological conditions.